Canada markets open in 3 hours 30 minutes

Defence Therapeutics Inc. (DTCFF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.56430.0000 (0.00%)
At close: 02:53PM EDT
Full screen
Loading interactive chart...
  • Newsfile

    Defence Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from Cervical Cancer

    Vancouver, British Columbia--(Newsfile Corp. - May 17, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the development of novel dual-acting AccumTM-linked protein vaccine, AccuVAC-PTE7, dedicated to protect from cervical cancer (prophylactic vaccine) or to treat (therapeutic vac

  • Newsfile

    Defence Therapeutics Announces Issuance Of a U.S. Patent Covering Its Pioneering Vaccine Platform Technology

    Vancouver, British Columbia--(Newsfile Corp. - April 7, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company primarily focused on the development of novel vaccines and drug delivery technologies, is pleased to announced that the United States Patent and Trademark Office (USPTO) has granted patent number US 11,291,717 ('717) covering its breakthrough vaccine platform technology for the treatment/prevention of

  • Newsfile

    Defence Therapeutics: An Anti-Cancer Solutions Platform Company Advancing Its Versatile Accum Technology

    Vancouver, British Columbia--(Newsfile Corp. - March 22, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF)("Defence" or the "Company"), a Canadian biotech company actively working on accelerating scientific discoveries and products development against cancer, is pleased to provide an overview of its current research and development progress in various cancer activities. In Q1 of 2022, Defence has signed an agreement with the Advanced Therapies Facilities (ATF) - GMP Unit